Page last updated: 2024-12-05

proglumide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Proglumide is a drug that inhibits the release of cholecystokinin (CCK), a hormone that stimulates the release of digestive enzymes from the pancreas and gallbladder contraction. It is used to treat gastrointestinal disorders such as irritable bowel syndrome and chronic pancreatitis. Proglumide has also been studied for its potential to treat cancer, particularly pancreatic cancer. Proglumide is synthesized through a multi-step process that involves reacting 4-chloro-N-(2,6-diethylphenyl)benzamide with N-methylpiperazine. The resulting compound is then treated with ethyl chloroformate and triethylamine to yield proglumide. Proglumide is being studied for its potential to inhibit the growth of pancreatic cancer cells by blocking the binding of CCK to its receptors. Proglumide has also been shown to reduce inflammation and pain in patients with chronic pancreatitis. While proglumide has shown promise in treating a variety of conditions, it is not without potential side effects. These side effects include diarrhea, nausea, vomiting, and constipation.'

Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4922
CHEMBL ID316561
CHEBI ID32058
CHEBI ID76266
SCHEMBL ID93339
SCHEMBL ID19994752
MeSH IDM0017675

Synonyms (155)

Synonym
AC-1274
chebi:32058 ,
nsc-757841
cr-242
CHEMBL316561 ,
w-5219 ,
promid
smr001233513
MLS002154246
BRD-A44863528-001-05-8
gtpl893
4-(benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid
DIVK1C_000684
KBIO1_000684
n~2~-(phenylcarbonyl)-n,n-dipropyl-alpha-glutamine
EU-0100832
SPECTRUM_001332
BSPBIO_002907
242 dl
xylamide
milide
einecs 229-567-4
binoside
ulcutin
milid
w 5219
xylamide (gastroprotective agent)
proglumidum [inn-latin]
brn 4151696
pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+-)-
cr 242
promide (parasympatholytic)
gastrotopic
midelid
glutaramic acid, 4-benzamido-n,n-dipropyl-, dl-
xyde
(+-)-4-benzamido-n,n-dipropylglutaramic acid
nulsa
proglumida [inn-spanish]
6620-60-6
PRESTWICK_602
BSPBIO_000319
LOPAC0_000832
PRESTWICK2_000240
PRESTWICK3_000240
BPBIO1_000351
IDI1_000684
SPECTRUM5_001591
AB00052206
proglumide
D01818
nulsa (tn)
proglumide (jp17/usan/inn)
NCGC00094163-03
NCGC00094163-02
KBIO2_004380
KBIOGR_000750
KBIO2_001812
KBIO2_006948
KBIOSS_001812
KBIO3_002407
SPBIO_001452
PRESTWICK1_000240
PRESTWICK0_000240
SPECTRUM2_001406
SPECTRUM4_000425
NINDS_000684
SPECTRUM3_001444
SPBIO_002240
SPECTRUM1501119
NCGC00094163-04
NCGC00094163-01
n2-(phenylcarbonyl)-n,n-dipropyl-a-glutamine
NCGC00015623-03
4-benzoylamino-5-dipropylamino-5-oxopentanoic acid
HMS2092D13
M-001
NCGC00015623-07
HMS502C06
FT-0654938
HMS1921F19
HMS1568P21
dl-proglumide
4-benzamido-5-(dipropylamino)-5-oxopentanoic acid
bdbm50014888
4-benzoylamino-4-dipropylcarbamoyl-butyric acid
HMS3262H05
HMS2095P21
pharmakon1600-01501119
nsc757841
tox21_110557
dtxcid003516
dtxsid7023516 ,
HMS2235B24
CCG-39024
NCGC00015623-05
NCGC00015623-04
NCGC00015623-06
proglumide [usan:inn:ban:jan]
unii-epl8w5565d
proglumida
epl8w5565d ,
proglumidum
nsc 757841
LP00832
AKOS015895810
proglumide [jan]
proglumide [who-dd]
proglumide [usan]
25727-74-6
pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-)-
proglumide [inn]
(+/-)-4-benzamido-n,n-dipropylglutaramic acid
proglumide [mi]
proglumide [mart.]
HMS3369D14
SCHEMBL93339
CHEBI:76266
NCGC00015623-10
4-benzamido-n,n-dipropylglutaramic acid
(+-)-proglumide
racemic proglumide
(rs)-proglumide
rac-n(2)-benzoyl-n,n-dipropyl-alpha-glutamine
tox21_110557_1
n(2)-benzoyl-n,n-dipropyl-alpha-glutamine
KS-1212
tox21_500832
NCGC00261517-01
DGMKFQYCZXERLX-UHFFFAOYSA-N
n2-benzoyl-n,n-dipropyl-alpha-glutamine
W-104770
CS-8029
HY-B1330
AB00052206_08
24485-90-3
sr-01000002970
SR-01000002970-2
dl-4-benzamido-n,n-dipropylglutaramic acid
pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-
SR-01000002970-7
SR-01000002970-4
SBI-0050809.P003
HMS3712P21
SCHEMBL19994752
DB13431
mfcd00055071
proglumide,(s)
Q7248362
BRD-A44863528-001-08-2
SDCCGSBI-0050809.P004
NCGC00015623-14
AMY374
4-(benzoylamino)-5-(dipropylamino)-5-oxo-pentanoic acid
BP166197

Research Excerpts

Overview

Proglumide (Pgm) is a known cholecystokinin (CCK) antagonist. Any changes in the level of CCK and in the number ofCCK receptors has been linked with SE.

ExcerptReferenceRelevance
"Proglumide (Pgm) is a known cholecystokinin (CCK) antagonist and any changes in the level of CCK and in the number of CCK receptors has been linked with SE."( Ameliorating effects of proglumide on neurobehavioral and biochemical deficits in animal model of status epilepticus.
Ahmad, M; Wadaan, MA, 2014
)
1.43
"Proglumide (PGM) is a CCK/gastrin receptor antagonist. "( [Effect of proglumide (PGM) on bile flow and contents in humans and animals].
Fang, XC, 1989
)
2.11

Effects

Proglumide has been studied for its ability to inhibit gastric secretion and to protect the gastroduodenal mucosa against injuries caused by pyloric ligation, hypothermic restraint stress, acetic acid, nonsteroid anti-inflammatory drugs, reserpine, cysteamine and the cytodestructing agents. It has been reported to antagonize sulfated cholecystokinin octapeptide (CCK-8) in peripheral tissue and in neurophysiological single unit preparations.

ExcerptReferenceRelevance
"Proglumide has been shown to be an in vivo inhibitor of secretagogue-stimulated gastric acid secretion. "( Evidence that proglumide and benzotript antagonize secretagogue stimulation of isolated gastric parietal cells.
Bali, JP; Magous, R, 1983
)
2.07
"Proglumide has no obvious effect on the growth of human large intestine carcinoma SW480 cell line, but can inhibit the growth-promoting effect of pentagastrin on large intestine carcinoma cells. "( Effects of proglumide, a gastrin receptor antagonist, on human large intestine carcinoma SW480 cell line.
He, S; He, Y; Shen, K, 1998
)
2.13
"Proglumide has been also shown to augment the analgesic effect of sustained release morphine in neuropathic pain."( Resolution of (RS)-proglumide using lipase from Candida cylindraceae.
Chirumamilla, RR; Marchant, R; Muralidhar, RV; Nigam, P; Ramachandran, VN, 2002
)
1.36
"Proglumide alone has no effect on sleep stages."( Hypnotic action of flunitrazepam is reversed by proglumide in rats.
De Saint Hilaire-Kafi, Z; Gaillard, JM; Vallet, PG, 1991
)
1.26
"Proglumide has been studied for its ability to inhibit gastric secretion and to protect the gastroduodenal mucosa against the injuries caused by pyloric ligation, hypothermic restraint stress, acetic acid, nonsteroid anti-inflammatory drugs, reserpine, cysteamine and the cytodestructing agents: 80% ethanol, 0.6 M HCl, 0.2 M NaOH, 25% NaCl and 30 mg of acetylsalicylic acid in 0.35 M HCl in rats. "( Gastric and duodenal antiulcer and cytoprotective effects of proglumide in rats.
Ageel, AM; Parmar, NS; Tariq, M, 1987
)
1.96
"Proglumide has been reported to antagonize sulfated cholecystokinin octapeptide (CCK-8) in peripheral tissue and in neurophysiological single unit preparations. "( Differential antagonism by proglumide of various CCK-mediated effects in mice.
Ambrose, FG; Autry, WL; Barbaz, BS; Gerber, R; Liebman, JM, 1985
)
2.01

Actions

Proglumide induced an increase in food intake in sham-operated rats confirming earlier results. Both proglumide and NS-398 inhibit the proliferation and induce the apoptosis of human gastric cells.

ExcerptReferenceRelevance
"Both proglumide and NS-398 inhibit the proliferation and induce the apoptosis of human gastric cells. "( [Effects of gastrin receptor antagonist and cyclooxygenase-2 inhibitor on proliferation and apoptosis of gastric cancer cell].
Cheng, YL; Ding, GX; Shao, Y; Su, H; Sun, WH; Xu, HC; Xue, YP; Zhang, LJ; Zhang, T, 2006
)
0.85
"Proglumide did not increase contractile activity of the omasum, abomasum and duodenum or the plasma concentration of immunoreactive cholecystokinin (CCK)."( Effect of intravenous infusion of proglumide on ruminal motility in conscious sheep (Ovis aries).
Onaga, T, 2007
)
1.34
"Only proglumide stimulated an increase in 30-min test meal intake and attenuated the satiating effect of CCK-8."( The effect of centrally administered CCK-receptor antagonists on food intake in rats.
Corp, ES; Curcio, M; Gibbs, J; Smith, GP, 1997
)
0.75
"Proglumide does not cause regression in advanced colorectal cancer but larger studies would be required to detect an effect on tumour growth."( A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer.
Ballantyne, KC; Charnley, RM; Jones, J; Morris, DL, 1990
)
1.28
"Proglumide induced an increase in food intake in sham-operated rats confirming earlier results."( The effect of vagotomy on the increase in food intake induced by the cholecystokinin antagonist, proglumide.
Davison, JS; Shillabeer, G, 1985
)
1.21

Treatment

Proglumide pretreatment did not alter any of these effects of brief footshock stress paradigm. In proglumide-treated animals, a significant increase in 3H-spiperone binding sites in the nucleus accumbens was observed. Co-treatment with proglomide and NS-398 have synergistic anticancer role.

ExcerptReferenceRelevance
"Proglumide pretreatment did not alter any of these effects of brief footshock stress paradigm."( Differential contribution of cholecystokinin receptors to stress-induced modulation of seizure and nociception thresholds in mice.
Dehpour, AR; Homayoun, H, 2004
)
1.04
"In proglumide-treated animals, a significant increase in 3H-spiperone binding sites in the nucleus accumbens was observed."( Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.
Csernansky, JG; Glick, S; Mellentin, J, 1987
)
1.09
"Treatment with proglumide and NS-398 significantly reduced the bcl-2 mRNA and protein expression in the MKN-45 cells (P < 0.05)."( [Effects of gastrin receptor antagonist and cyclooxygenase-2 inhibitor on proliferation and apoptosis of gastric cancer cell].
Cheng, YL; Ding, GX; Shao, Y; Su, H; Sun, WH; Xu, HC; Xue, YP; Zhang, LJ; Zhang, T, 2006
)
0.67
"Co-treatment with proglumide and NS-398 have synergistic anticancer role."( [Effects of gastrin receptor antagonist and cyclooxygenase-2 inhibitor on proliferation and apoptosis of gastric cancer cell].
Cheng, YL; Ding, GX; Shao, Y; Su, H; Sun, WH; Xu, HC; Xue, YP; Zhang, LJ; Zhang, T, 2006
)
0.66
"Pretreatment with proglumide accelerated GP synthesis in the normal glandular stomach and restored the GP decrease caused by fasting."( Effect of proglumide on glycoprotein synthesis in aspirin-induced gastric erosions in rats.
Iwaki, K; Kimura, K; Sanai, K; Umetsu, T, 1980
)
0.99
"Pretreatment with proglumide, (20 mg/kg i.p.) a gastrin/cholecystokinin (CCK) receptor antagonist, prevented the pentagastrin-induced changes in SS level and binding as well as the inhibitory effect of SS on AC activity in pancreatic acinar cell membranes."( The effect of pentagastrin on the somatostatin receptor/effector system in rat pancreatic acinar membranes.
Alvaro-Alonso, I; Arilla, E; Muñoz-Acedo, G, 1994
)
0.61
"Pretreatment with proglumide (400 mg/kg i.p.) antagonized this effect."( Proglumide antagonizes cholecystokinin effects on plasma glucose and insulin in rats in vivo.
Ammon, HP; Verspohl, EJ; Wunderle, G, 1988
)
2.04

Toxicity

ExcerptReferenceRelevance
" CR-1409 completely abolished the adverse effects of hydrocortisone on pancreatitis."( Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis.
Gomez, G; Green, D; Rajaraman, S; Thompson, JC; Townsend, CM; Uchida, T, 1989
)
0.28
" Clinical symptoms and physical signs, laboratory tests, and adverse reactions were checked every 6 weeks as efficacy/tolerability criteria."( Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.
Di Prima, F; Militello, C; Pedrazzoli, S; Sperti, C, 1997
)
0.3
" Proglumide was well tolerated at all doses without any serious adverse events."( Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Bansal, S; Cao, H; Cheema, A; Gay, MD; Kwagyan, J; Lewis, JH; Nadella, S; Rabiee, A; Shivapurkar, N; Smith, CI; Smith, JP, 2022
)
1.63

Pharmacokinetics

ExcerptReferenceRelevance
"In order to explain the long-term therapeutic activity of (+/-)-4-benzamide-N,-di-n-propylglutaramic acid (proglumide, Milid) a pharmacokinetic study was carried out in rats by three administration routes."( Pharmacokinetic approach to proglumide long-term activity.
Bignamini, AA; Casula, PL; Rovati, AL, 1979
)
0.77
" The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11."( Pharmacokinetics and tolerance of repeated oral doses of loxiglumide.
Chisté, R; Giacovelli, G; Rovati, LC; Setnikar, I, 1989
)
0.28
" infusion the plasma levels were consistent with an open two-compartment pharmacokinetic model represented by the equation C (mg/l) = 43."( Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.
Chisté, R; Makovec, F; Rovati, LC; Setnikar, I; Warrington, SJ, 1988
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"A double-blind placebo controlled trial was carried out in 32 hospitalized patients with various rheumatic disorders to assess the therapeutic effectiveness and gastric tolerance of indomethacin (150 mg/day) used alone or in combination with proglumide (900 mg/day)."( Double-blind comparison of the antirheumatic activity and gastric side-effects of indomethacin used alone or in combination with a gastro-protective agent, proglumide.
Pipitone, V, 1976
)
0.64

Bioavailability

ExcerptReferenceRelevance
" These results suggest that the half-life of loxiglumide given by oral route is longer than that by sc route or that the bioavailability of oral loxiglumide is higher than that of sc dose."( Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.
Otsuki, M; Watanabe, N, 1993
)
0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8 stimulated pancreatic protein secretion in anesthetized rats. Administration of aspirin decreased the gastric mucosal hexosamine and induced the onset of ulcer.

ExcerptRelevanceReference
" Since human pharmacokinetics was found to be rather similar to that in rats, it can be extrapolated that steady state plasma level of drug during therapeutic dosage regimen should range around 60% of peak level of single administration."( Pharmacokinetic approach to proglumide long-term activity.
Bignamini, AA; Casula, PL; Rovati, AL, 1979
)
0.55
" Both antagonists caused a rightward shift of the dose-response curve for CCK-8s on the monkey iris sphincter."( Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists.
Almegård, B; Bill, A; Stjernschantz, J, 1992
)
0.28
"The aim of this study was to conduct dose-response studies of the effect of cholestyramine, alone or in combination with a test meal, on gallbladder emptying studied by ultrasonography in 31 healthy volunteers."( Opposite effects of cholestyramine and loxiglumide on gallbladder dynamics in humans.
Albano, O; Baldassarre, G; Belfiore, A; Palasciano, G; Portincasa, P, 1992
)
0.28
" Omeprazole, which suppresses acid very effectively, may be problematic in the critically ill, limited by its oral dosage form, acid-labile properties, and potential drug interactions."( Controlling gastric pH: the impact of newer agents on the critically ill patient.
Earnest, DL, 1990
)
0.28
" Proglumide both shifted the dose-response curve for morphine analgesia to the left and prolonged morphine's duration of action."( Proglumide selectively potentiates supraspinal mu 1 opioid analgesia in mice.
Bodnar, RJ; Pasternak, GW; Paul, D, 1990
)
2.63
" CR 1409 caused a rightward and parallel shift in the dose-response curve of CCK-8-stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive mechanism of inhibition."( The effect of CR 1409, a potent CCK receptor antagonist, on basal and stimulated pancreatic secretion in rat.
Nagy, I; Pap, A; Takács, T; Varró, V, 1990
)
0.28
" The model was used to demonstrate a dose-response curve to bolus administration of exogenous cholecystokinin (0."( In vivo comparison of inhibition with proglumide and CR-1409 of cholecystokinin-induced pressure in the biliary tract of the guinea pig.
Hashimoto, T; MacLellan, DG; Poston, GJ; Thompson, JC; Townsend, CM; Upp, JR, 1990
)
0.55
"9 micrograms tetrodotoxin intracamerally had no clear effect on the dose-response relationship for CCK-8."( Cholecystokinin causes contraction of the pupillary sphincter in monkeys but not in cats, rabbits, rats and guinea-pigs: antagonism by lorglumide.
Almegård, B; Andersson, SE; Bill, A, 1990
)
0.28
" Schild analysis of the CCK dose-response curve indicates that L-364,718 and CR1409 exert their inhibitory effects on CCK-8-stimulated chief cell responses in a competitive manner."( Effects of CCK-receptor antagonists on CCK-stimulated pepsinogen secretion and calcium increase in isolated guinea pig gastric chief cells.
Konda, Y; Matozaki, T; Nagao, M; Nakano, O; Nishisaki, H; Sakamoto, C, 1990
)
0.28
" Biphasic dose-response curves to cholecystokinin for amylase release shifted to the right with an increase in the concentration of the drug."( CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto, Y; Kuzuya, T; Yamamoto, R, 1987
)
0.27
" L364,718 (3-100 nM), proglumide (1-10 mM), and the proglumide derivative CR1409 (1-30 microM) each caused a progressive rightward shift in the CCK-8 dose-response curve without a change in maximal amylase secretion."( Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Liang, JP; Louie, DS; Owyang, C, 1988
)
0.59
" The caerulein dose-response curve was gradually shifted to the right by increasing doses of CR 1409, indicating competitive-like kinetics."( Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Grendell, JH; Niederau, C; Niederau, M; Strohmeyer, G, 1989
)
0.28
" Loxiglumide caused a concentration-dependent rightward shift of the dose-response curve for CCK-8-stimulated amylase release without altering the maximal response."( [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
Baba, S; Fujii, M; Fujisawa, T; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1989
)
0.57
" In the isolated acini, CR 1392 caused a parallel rightward shift of the dose-response curve for amylase secretion stimulated by cholecystokinin octapeptide (CCK-8)."( Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat.
Baba, S; Fujii, M; Fujisawa, T; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1989
)
0.62
" Atropine shifted the dose-response curve of CCK-OP in pylorus, duodenum and antrum to the right suggesting a neural action of CCK-OP."( Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
Allescher, HD; Daniel, EE; Fox, JE; Kostolanska, F; Rovati, LA, 1989
)
0.28
" Close correlation between the decrease in gall bladder volume and the dosage of CCK or the increments in plasma CCK-bioactivity was observed."( CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
Bogdal, J; Konturek, JW; Konturek, SJ; Kurek, A; Oleksy, J; Rovati, L, 1989
)
0.28
" In chronic pancreatic fistula dogs, dose-response studies were performed to determine the effect of proglumide on the pancreatic responses to octapeptide of CCK (CCK-OP), intravenous bethanechol, intraduodenal amino acids, and intraduodenal fat."( Role of cholecystokinin in pancreatic exocrine response to intraluminal amino acids and fat.
Stabile, BE; Stubbs, RS, 1985
)
0.49
" Proglumide shifted the dose-response curves of the inhibitory as well as excitatory effects of CCK analogues to the right."( Structure-activity relationship of subtypes of cholecystokinin receptors in the cat lower esophageal sphincter.
Goyal, RK; Rattan, S, 1986
)
1.18
" Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8 stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition."( The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats.
Nagy, I; Pap, A; Takács, T; Varró, V, 1988
)
1.19
" The compounds are competitive and specific CCK-antagonists, causing a parallel right shift of the cumulative dose-response curve of the agonist."( New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.
Bani, M; Chistè, R; Makovec, F; Pacini, MA; Rovati, LA; Setnikar, I, 1985
)
0.27
" Dose-response curves to CCK for amylase release shifted to the right with increase in proglumide concentration."( In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini.
Akanuma, Y; Iwamoto, Y; Nakamura, R, 1984
)
0.78
" Inhibition by proglumide was competitive and resulted in a parallel rightward shift of the cholecystokinin dose-response curve."( Cholecystokinin-induced contraction of dispersed smooth muscle cells.
Collins, SM; Gardner, JD, 1982
)
0.62
" In the case of secretagogue stimulation (1) benzotript slightly affected histamine-induced AP (15% inhibition at 5 X 10(-3) M), proglumide did not; (2) both proglumide and benzotript inhibited in a non-competitive manner acetylcholine-induced AP; (3) these isolated cells were sensitive to gastrin and the dose-response curve for the stimulant was biphasic (maximum for 1 X 10(-9) M), suggesting a desensitization mechanism."( Evidence that proglumide and benzotript antagonize secretagogue stimulation of isolated gastric parietal cells.
Bali, JP; Magous, R, 1983
)
0.83
" Administration of aspirin decreased the gastric mucosal hexosamine and induced the onset of ulcer, while administration of proglumide suppressed the gastric lesions in proportion to dosage and correspondingly prevented a decrease of the hexosamine."( The role of gastric mucosal hexosamine in aspirin-induced ulcers.
Aono, M; Moriga, M; Murakami, M; Uchino, H, 1980
)
0.47
" Pre-treatment with the unselective tachykinin receptor antagonist spantide or the NK1 receptor selective antagonist GR82334 caused a rightward shift of the dose-response curves for both fragments, while the CCK receptor antagonist loxiglumide had no inhibitory effect."( CGRP(8-37) and CGRP(32-37) contract the iris sphincter in the rabbit eye: antagonism by spantide and GR82334.
Almegård, B; Andersson, SE, 1993
)
0.29
" To further evaluate the role of cholecystokinin (CCK) in regulating acid output in humans, dose-response curves were constructed to CCK8 or G17 (6."( Cholecystokinin is a physiological regulator of gastric acid secretion in man.
Aufderhaar, U; Bauerfeind, P; Beglinger, C; Burckhardt, B; Delco, F; Ensinck, JW; Gyr, K; Ketterer, S; Meier, R, 1994
)
0.29
" The antagonism was competitive in nature because these three compounds caused a parallel rightward shift of the dose-response curve for CCK-8-stimulated amylase secretion, without altering the maximal increase."( Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama, T; Otsuki, M, 1994
)
0.29
" TP-680 caused a parallel rightward shift of the dose-response curve for CCK-8-stimulated amylase release as did MK-329 and loxiglumide."( Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
Akiyama, T; Hirohata, Y; Otsuki, M; Shirohara, H; Tachibana, I; Yamamoto, M, 1996
)
0.29
" This rightward shift of the morphine dose-response curve was reversed by the intrathecal administration of either the CCKA receptor antagonist, lorglumide, or the CCKB receptor antagonist, PD135, 158."( Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin.
Fujimoto, JM; Lin, W; Rady, JJ, 1998
)
0.3
" TS-941 caused a parallel rightward shift of the entire dose-response curve for CCK-8-stimulated amylase release without altering the maximal increase, as did devazepide and loxiglumide."( Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Akiyama, T; Hirohata, Y; Kihara, Y; Otsuki, M; Tashiro, M, 1999
)
0.3
" Morphine analgesia was inhibited by dynorphin as shown by a rightward shift of the morphine dose-response curve."( Antianalgesic action of dynorphin A mediated by spinal cholecystokinin.
Fujimoto, JM; Holmes, BB; Rady, JJ, 1999
)
0.3
"A multicenter dose-response controlled trial was conducted at 110 institutions in Japan from June 1993 to December 1994."( Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Matsuno, S; Satake, K; Shiratori, K; Takeuchi, T, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
drug metabolitenull
xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
cholecystokinin antagonistA hormone antagonist that inhibits the action of the peptide hormone cholecystokinin.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
delta-opioid receptor agonistnull
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzamides
dicarboxylic acid monoamide
glutamine derivativeA glutamic acid derivative resulting from reaction of glutamine acid at the amino group, the carboxy group, or the side-chain carboxamide, or from the replacement of any hydrogen by a heteroatom. The definition normally excludes peptides containing glutamine residues.
racemateA racemate is an equimolar mixture of a pair of enantiomers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency63.09570.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency7.94330.044717.8581100.0000AID485294
endonuclease IVEscherichia coliPotency14.12540.707912.432431.6228AID1708
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.62280.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency13.33320.001628.015177.1139AID1259385
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency1.25890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)250.00000.00000.43624.3000AID53038
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)800.00000.00041.13803.5000AID52568
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID50966Inhibition of binding of [125I]gastrin to Cholecystokinin type B receptor from guinea pig gastric glands1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID74353In vitro inhibitory activity for binding of [125I](Nle11)-HG-13 to gastrin receptor on isolated rabbit gastric mucosal cells.1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin.
AID190223Agonistic activity against gastrin induced acid secretion in the anesthetized rats; No agonist activity at doses as high as 3 mg/kg1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin.
AID52568Inhibition of binding of [125I]- CCK-33 to guinea pig cortex1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID177912Inhibition of gastrin stimulated acid secretion in in situ perfused rat stomach1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Structure-activity relationships of C-terminal tri- and tetrapeptide fragments that inhibit gastrin activity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID88496Inhibitory activity against binding of [125I](Nle11)-HG-13 to Histamine H2 receptor in vitro1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Structure-activity relationships of C-terminal tri- and tetrapeptide fragments that inhibit gastrin activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID178945Effective dose required to inhibit gastrin-induced acid secretion in the in situ perfused rat stomach (anesthetized rat)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin.
AID53038Inhibition of binding of [125I]- CCK-33 to rat pancreas1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1987Arzneimittel-Forschung, Nov, Volume: 37, Issue:11
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (786)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990269 (34.22)18.7374
1990's350 (44.53)18.2507
2000's105 (13.36)29.6817
2010's47 (5.98)24.3611
2020's15 (1.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.01 (24.57)
Research Supply Index6.83 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index60.00 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (39.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials93 (11.23%)5.53%
Reviews26 (3.14%)6.00%
Case Studies1 (0.12%)4.05%
Observational0 (0.00%)0.25%
Other708 (85.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Single-dose Pharmacokinetic (PK) Assessment of Oral Proglumide in Those With Hepatic Impairment [NCT04814602]Early Phase 111 participants (Actual)Interventional2021-03-30Completed
Phase I Study of Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic DuctalAdenocarcinoma [NCT06017323]Phase 10 participants (Actual)Interventional2023-10-31Withdrawn(stopped due to STUDY00006987)
A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months [NCT05551858]Phase 1/Phase 232 participants (Anticipated)Interventional2022-11-17Recruiting
Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH) [NCT04152473]Phase 118 participants (Actual)Interventional2019-12-13Completed
Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in Pancreatic Cancer [NCT05827055]Phase 230 participants (Anticipated)Interventional2024-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]